InsiderClue
Stocks · Health care · Biological Products, (No Diagnostic Substances)

Kyverna Therapeutics, Inc.

KYTX Clue Score44
United States Fiscal year ends December CIK 0001994702
$6.39 +3.40% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $6.39 −9.49% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 8 Feb 2024. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
Operating incomeNet income
Fiscal year 2023Operating income−62.4Net income−60.4EPS, diluted−89.61Fiscal year 2024Operating income−142.6Net income−127.5EPS, diluted−3.33Fiscal year 2025Operating income−169.8Net income−161.3EPS, diluted−3.64
FY2023FY2024FY2025
Operating income −62.4 −142.6 −169.8
Net income −60.4 −127.5 −161.3
Growth
EPS, diluted −89.61 −3.33 −3.64

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2023Operating cash flow−52.4Capital expenditure−0.6Free cash flow−53.0Fiscal year 2024Operating cash flow−114.3Capital expenditure−2.2Free cash flow−116.5Fiscal year 2025Operating cash flow−153.7Capital expenditure−0.0Free cash flow−153.7
FY2023FY2024FY2025
Operating cash flow −52.4 −114.3 −153.7
Capital expenditure −0.6 −2.2 −0.0
Free cash flow −53.0 −116.5 −153.7
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
CashTotal debt
Fiscal year 2023Cash34.6Shareholders’ equity−13.1Fiscal year 2024Cash96.6Shareholders’ equity266.6Fiscal year 2025Cash124.1Total debt24.7Net cash (debt)99.4Shareholders’ equity232.3Debt to equity0.11
FY2023FY2024FY2025
Cash 34.6 96.6 124.1
Total debt n/a n/a 24.7
Net cash (debt) n/a n/a 99.4
Shareholders’ equity −13.1 266.6 232.3
Debt to equity n/a n/a 0.11

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Ratios

Percentages worked out from the filed figures; debt to equity in times. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Returns
n/a −47.8% −69.4%
−80.3% −41.8% −54.9%
Balance and payout
n/a n/a 0.11
34.6% 12.5% 20.9%